Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
New Data to be Presented at ASCO Shows Survival Benefit in Complete and Partial Responders Compared with Chemotherapy Alone
Genta Incorporated (OTC Bulletin Board: GNTA) announced the results of long-term followup from a Phase 3 trial of the Company\'s lead oncology product, Genasense(R) (oblimersen sodium) Injection, in patients with chronic lymphocytic leukemia (CLL). With 5 years of followup, new data show that patients who achieved either a complete response (CR -- the trial\'s primary endpoint) or a partial response (PR) have also achieved a statistically significant increase in overall survival. The data will be featured in an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2, 2008.
- Published: 29 May 2008
- Written by Editor